{
    "organizations": [],
    "uuid": "eaf6373dd68bcaaf2c58af747f89afd01fc5649f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-esperion-announces-positive-top-li/brief-esperion-announces-positive-top-line-results-from-phase-2-study-of-bempedoic-acid-added-on-to-a-pcsk9-inhibitor-idUSFWN1R90CK",
    "ord_in_thread": 0,
    "title": "BRIEF-Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA\n* ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT WITH 30% ADDITIONAL LDL-C LOWERING\n* ESPERION THERAPEUTICS INC - BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR OBSERVED TO BE SAFE AND WELL-TOLERATED IN THIS STUDY\n* ESPERION THERAPEUTICS - TO SUBMIT NDAS TO U.S. FDA FOR BEMPEDOIC ACID, BEMPEDOIC ACID/EZETIMIBE COMBINATION PILL FOR LDL-C-LOWERING INDICATIONS BY Q1 2019 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-03-27T19:43:00.000+03:00",
    "crawled": "2018-03-28T18:42:06.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "esperion",
        "therapeutic",
        "inc",
        "esperion",
        "announces",
        "positive",
        "result",
        "phase",
        "study",
        "bempedoic",
        "acid",
        "pcsk9",
        "inhibitor",
        "patient",
        "hypercholesterolemia",
        "esperion",
        "therapeutic",
        "inc",
        "study",
        "met",
        "primary",
        "endpoint",
        "additional",
        "lowering",
        "esperion",
        "therapeutic",
        "inc",
        "bempedoic",
        "acid",
        "pcsk9",
        "inhibitor",
        "observed",
        "safe",
        "study",
        "esperion",
        "therapeutic",
        "submit",
        "ndas",
        "fda",
        "bempedoic",
        "acid",
        "bempedoic",
        "combination",
        "pill",
        "indication",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}